# Oligo-PRESTO (NCT04115007)

> Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04115007
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: UNICANCER
- Conditions: Oligometastatic Hormone Sensitive Prostate Cancer
- Interventions: Stereotactic Body Radiotherapy (SBRT) + Standard of care; Standard of care
- Enrollment: 550
- Primary outcome: Castration-resistant prostate cancer free survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=oligo-presto-nct04115007